Chardan Capital Reiterates Buy on Tenaya Therapeutics, Maintains $23 Price Target
Portfolio Pulse from richadhand@benzinga.com
Chardan Capital analyst Geulah Livshits has reiterated a 'Buy' rating on Tenaya Therapeutics (NASDAQ:TNYA) and maintained a price target of $23.
August 14, 2023 | 8:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chardan Capital has reiterated a 'Buy' rating on Tenaya Therapeutics and maintained a price target of $23.
The reiteration of a 'Buy' rating by Chardan Capital indicates a positive outlook for Tenaya Therapeutics. The maintained price target of $23 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100